Who Exports Syringe from India — 291 Suppliers Behind a $179.9M Market
India's syringe export market is supplied by 291 active exporters who collectively shipped $179.9M across 3,522 shipments. GLAND PHARMA LTD leads with a 34.7% market share, followed by GLAND PHARMA LIMITED and INDIAN IMMUNOLOGICALS LIMITED. The top 5 suppliers together control 84.6% of total export value, reflecting a concentrated market structure.
Top Syringe Exporters from India — Ranked by Export Value
GLAND PHARMA LTD is the leading syringe exporter from India, holding a 34.7% share of the $179.9M market across 3,522 shipments from 291 exporters. The top 5 suppliers — GLAND PHARMA LTD, GLAND PHARMA LIMITED, INDIAN IMMUNOLOGICALS LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, MYLAN LABORATORIES LIMITED — collectively control 84.6% of total export value, indicating a highly concentrated market. Individual shares are: GLAND PHARMA LTD (34.7%), GLAND PHARMA LIMITED (18.4%), INDIAN IMMUNOLOGICALS LIMITED (15.8%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (12.8%), MYLAN LABORATORIES LIMITED (2.9%).
Top Syringe Exporters from India
Ranked by export value · 291 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | GLAND PHARMA LTD ENOXAPARIN SODIUM INJECTION USP, 40MG PRE-FILLEDSYRINGESABHAYRAB 0.5ML BPABHAYRAB 0.5ML B.P | $62.4M | 22 | 34.7% |
| 2 | GLAND PHARMA LIMITED ENOXAPARIN SODIUM INJECTION USP, 40MG PRE-FILLEDSYRINGESABHAYRAB 0.5ML BPABHAYRAB 0.5ML B.P | $33.1M | 19 | 18.4% |
| 3 | INDIAN IMMUNOLOGICALS LIMITED ABHAYRAB 0.5ML B.PABHAYRAB 0.5ML BPABHAYRAB 0.5ML | $28.5M | 20 | 15.8% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED SUMATRIPTAN SUN 6 MG/ 0.5 ML -GST INVOICE NOSUMATRIPTAN SUN 6MG/0.5ML -GST INVOICE NO.EI2TEMPIL 6MG INJ 1*12 PFS DE -GST INVOICE NO.EI | $23.0M | 6 | 12.8% |
| 5 | MYLAN LABORATORIES LIMITED DENTAL GOODS :- LIGHT CURE COMPOSITE SYRINGE - KRIS N CERAMDENTAL GOODS :- FLOWABLE COMPOSITE SYRINGE - KRIS N FLOW | $5.2M | 6 | 2.9% |
| 6 | JODAS EXPOIM PRIVATE LIMITED FULVESTRANT INJECTION 250MG/5ML #1FULVESTRANT INJECTION 250MG/5ML PRE-FILLED SYRINGE NOSENOXAPARIN INJECTION 60MG IN 0.6ML PREFILLED SYRINGE | $3.5M | 2 | 1.9% |
| 7 | SUN PHARMACEUTICAL INDUSTRIES LTD SUMATRIPTAN SUN 6 MG/ 0.5 ML -GST INVOICE NOSUMATRIPTAN SUN 6MG/0.5ML -GST INVOICE NO.EI2TEMPIL 6MG INJ 1*12 PFS DE -GST INVOICE NO.EI | $3.3M | 1 | 1.9% |
| 8 | BRAWN LABORATORIES LIMITED ABHAYRAB 0.5ML BPABHAYRAB 0.5ML B.PFULVESTRANT INJECTION 250MG/5ML PRE-FILLED SYRINGE NOS | $3.2M | 5 | 1.8% |
| 9 | CONTACARE OPHTHALMICS AND DIAGNOSTICS SUMATRIPTAN SUN 6 MG/ 0.5 ML -GST INVOICE NOENOXAPARIN SODIUM INJECTION USP, 40MG PRE-FILLEDSYRINGESABHAYRAB 0.5ML BP | $1.9M | 30 | 1.1% |
| 10 | INDIAN IMMUNOLOGICALS LTD ABHAYRAB 0.5ML B.PABHAYRAB 0.5ML BPABHAYRAB 0.5ML | $1.7M | 7 | 0.9% |
| 11 | INTAS PHARMACEUTICALS LIMITED ENOXAPARIN SODIUM INJECTION USP, 40MG PRE-FILLEDSYRINGES | $1.7M | 11 | 0.9% |
| 12 | EUGIA PHARMA SPECIALITIES LIMITED ENOXAPARIN SODIUM INJECTION USP, 40MG PRE-FILLEDSYRINGES | $1.4M | 1 | 0.8% |
| 13 | VIRCHOW BIOTECH PRIVATE LIMITED | $1.1M | 1 | 0.6% |
| 14 | CAPLIN POINT LABORATORIES LIMITED | $975.0K | 4 | 0.5% |
| 15 | CONTACARE OPHTHALMICS DIAGNOSTICS SUMATRIPTAN SUN 6 MG/ 0.5 ML -GST INVOICE NOENOXAPARIN SODIUM INJECTION USP, 40MG PRE-FILLEDSYRINGESABHAYRAB 0.5ML BP | $774.0K | 20 | 0.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Syringe exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| GLAND PHARMA LIMITED | Approved | Yes | Yes | 371 | Received USFDA approval for Cangrelor for Injection on August 12, 2025. |
| EUGIA PHARMA SPECIALITIES LIMITED | Warning Letter August 202 | Unknown | Unknown | Not verified | Received FDA warning letter for CGMP violations at Unit III facility. |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Unknown | Unknown | Multiple | Multiple FDA filings for prescription medications. (fda.report) |
| INTAS PHARMACEUTICALS LIMITED | Unknown | Yes | Yes | Not verified | EU GMP certified in April 2007; first Indian company to receive such certificati |
| CAPLIN POINT LABORATORIES LIMITED | Approved | Unknown | Unknown | Not verified | Received USFDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic |
TransData Nexus reviewed the regulatory standing of 5 leading Syringe exporters from India. 3 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 2 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Syringe sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a central hub for pharmaceutical manufacturing. The city is home to Genome Valley, India's first biotech cluster, and hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. This concentration of industry leaders contributes significantly to the production of active pharmaceutical ingredients (APIs), vaccines, biologics, and biosimilars.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is recognized as a major pharmaceutical manufacturing cluster, contributing nearly 28% of India's pharmaceutical production. This region is home to prominent companies such as Zydus Cadila, Intas Pharmaceuticals, Torrent Pharmaceuticals, and Cadila Pharmaceuticals. The strong support infrastructure, including ports, roads, power, and water, enhances the region's capacity for large-scale pharmaceutical manufacturing.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being the financial capital, provides a robust infrastructure and connectivity that facilitates the export of pharmaceutical products. The region hosts numerous pharmaceutical companies, including Alkem Laboratories and Unichem Laboratories, which contribute to the manufacturing and export of various pharmaceutical formulations.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in the Solan district of Himachal Pradesh, has emerged as a significant pharmaceutical manufacturing hub, housing over 1,000 pharmaceutical units. The region's growth is attributed to favorable government policies, world-class infrastructure, and proximity to key markets. Baddi's strategic location and tax incentives have attracted numerous pharmaceutical companies, making it a backbone of India's healthcare manufacturing.
5Sourcing Recommendations
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and quality standards of suppliers in Hyderabad and Ahmedabad-Vadodara, given their prominence in API and formulation production.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline logistics and distribution channels for international markets.
- Consider Cost Advantages: Explore sourcing opportunities in Baddi-Nalagarh to benefit from tax incentives and cost-effective manufacturing solutions.
- Ensure Regulatory Compliance: Verify that potential suppliers adhere to international regulatory standards, such as those set by the FDA, EMA, WHO, CDSCO, and NPPA, to ensure product quality and compliance.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Syringe exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires remaining stake in Taro Pharmaceuticals
Sun Pharma entered into a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals for $347.73 million. - IMPACT: This acquisition is expected to enhance Sun Pharma's product portfolio, potentially increasing its syringe exports.
Impact: This acquisition is expected to enhance Sun Pharma's product portfolio, potentially increasing its syringe exports.
Common Questions — Syringe Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which syringe supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, GLAND PHARMA LTD leads with 619 recorded shipments worth $62.4M. GLAND PHARMA LIMITED (234 shipments) and INDIAN IMMUNOLOGICALS LIMITED (158 shipments) are also established high-volume exporters.
Q How many syringe manufacturers are there in India?
India has 291 active syringe exporters with a combined export market of $179.9M across 3,522 shipments to 154 countries. The top 5 suppliers hold 84.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for syringe from India?
Average FOB unit price: $19.21 per unit, ranging from $0.00 to $1680.17. Average shipment value: $51.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 291 verified Indian exporters of Syringe ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,522 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 154 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,522 Verified Shipments
291 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists